Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade ...

Blood transfusions are essential for patients with cancer, sickle cell disease, and traumatic injuries, but blood supply ...

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing ...

The United States’ official exit from the World Health Organization (WHO) is set to be finalized today, Thursday January 22, ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pharmaceutical Executive | Publications | Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

Pharmaceutical Executive: What was Daiichi Sankyo's strategy for preparing for the JP Morgan Healthcare Conference? Ken ...

AI can accelerate drug discovery, clinical development, and patient access, but regulatory hurdles remain. Anders Romare, ...

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights ...

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical ...